How to integrate early access programmes into your pharma market access strategy
Access is everything for rare disease patients, who often [...]
Access is everything for rare disease patients, who often [...]
The line between medical affairs and drug commercialisation functions [...]
The actionable, real-time feedback medical science liaisons (MSL) gather [...]
Submitting a dossier to the EMA or MHRA is [...]
Reporting serious adverse events (SAE) is integral to running [...]
Bringing a new drug to market is a complex, [...]
Pharmacovigilance (PV) plays a crucial role in assuring patient [...]
Biotech and pharmaceutical companies face numerous challenges when commercialising [...]
The path to regulatory approval for rare disease treatments [...]
Innovation is often the key to unlocking life-changing treatments [...]